Improved benefit/risk ratio of higher-dose metoclopramide therapy during cisplatin-induced emesis.

Abstract

Metoclopramide (Paspertin) was infused intravenously in the high doses of 1.75, 3.5, 7.0, and 14 mg/kg body wt. per treatment cycle as antiemetic therapy for cisplatin-induced emesis (363 cycles, 25-120 mg/m2). The antiemetic potency of metoclopramide increased in a log linear manner, giving from 40% to 95% protection against emesis. Gastrointestinal motility showed a similar increase, i.e. diarrhoea. In contrast, the extrapyramidal reactions, namely akathisia, rigidity and acute dystonia, did not show a dose-dependent increase in frequency and remained constant over the dose range of 3.5-14 mg/kg per cycle. The results suggest increasing benefit of metoclopramide treatment with increasing doses of the drug.

• Authors: R Saller, D Hellenbrecht, A Hellstern, H Hess
• Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 29 Issue 3 Pg. 311-2 ( 1985) ISSN: 0031-6970 [Print] Germany
• PMID: 4076327 (Publication Type: Journal Article)

Chemical References

• Metoclopramide
• Cisplatin

Topics

• Basal Ganglia Diseases (chemically induced)
• Cisplatin (adverse effects)
• Dose-Response Relationship, Drug
• Hemodynamics (drug effects)
• Humans
• Metoclopramide (administration & dosage, adverse effects, therapeutic use)
• Risk
• Vomiting (chemically induced, drug therapy)